1 |
NCT02344355 |
Recruiting |
A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme |
|
- Drug: Temozolomide
- Radiation: radiation therapy
- Drug: Ascorbic Acid
|
Interventional |
Phase 2 |
- University of Iowa
- Holden Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Progression Free Survival (PFS)
- Adverse Event Frequency
|
90 |
All |
18 Years and older (Adult, Senior) |
NCT02344355 |
201504786 |
|
March 13, 2017 |
April 2020 |
December 2021 |
January 22, 2015 |
April 21, 2017 |
|
- Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
|
2 |
NCT03335670 |
Recruiting |
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors |
|
|
Interventional |
Early Phase 1 |
- Yusuf Menda
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- (and 2 more...)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Determine biodistribution (pharmacokinetic parameters) of [68Ga]Pentixafor in patients with neuroendocrine tumors (NETs)
- Determine the repeatability of [68Ga]Pentixafor uptake in known neuroendocrine tumor lesions
- Compare standardized uptake values of [68Ga]Pentixafor and [68Ga]DOTATATE in known neuroendocrine tumor lesions
- Correlate the uptake of [68Ga]Pentixafor and [68Ga]DOTATATE (NetSpot) in known neuroendocrine tumor lesions with expression of receptors (CXCR4 and SSTR2) in biopsy tissue samples.
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT03335670 |
201708705 P50CA174521 |
|
November 3, 2017 |
October 1, 2019 |
December 31, 2020 |
November 8, 2017 |
January 9, 2018 |
|
- Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
|
3 |
NCT03044977 |
Recruiting |
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors |
- Neuroendocrine Tumor, Malignant
- Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
|
- Drug: 90Y-DOTA-3-Tyr-Octreotide
- Drug: 131I-MIBG
|
Interventional |
Early Phase 1 |
- David Bushnell
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- (and 2 more...)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- glomular filtration rate (eGFR)
- urine protein
- platelet count decreased
- (and 3 more...)
|
20 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03044977 |
201608857 P50CA174521-02 |
|
May 7, 2017 |
December 31, 2020 |
December 31, 2022 |
February 7, 2017 |
April 17, 2018 |
|
- Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
|
4 |
NCT02420314 |
Recruiting |
Pharmacological Ascorbate for Lung Cancer |
- Carcinoma, Non-Small-Cell Lung
|
- Drug: Paclitaxel
- Drug: Carboplatin
- Drug: Ascorbic Acid
|
Interventional |
Phase 2 |
- Muhammad Furqan
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- (and 3 more...)
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tumor response
- Progression free survival (PFS)
- Overall survival (OS)
- Adverse Event Frequency
|
57 |
All |
18 Years and older (Adult, Senior) |
NCT02420314 |
201412760 3P30CA086862 |
|
April 2015 |
December 2020 |
December 2025 |
April 17, 2015 |
January 26, 2018 |
|
- Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
|
5 |
NCT03506139 |
Not yet recruiting New |
Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma |
- Glioblastoma
- Glioblastoma Multiforme
|
- Radiation: External beam radiation therapy
|
Interventional |
Phase 2 |
- John M. Buatti
- Holden Comprehensive Cancer Center
- University of Iowa
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Progression free survival (PFS)
- Identifying tissue at risk of recurrence
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT03506139 |
201801819 |
|
April 30, 2018 |
December 31, 2024 |
December 31, 2026 |
April 23, 2018 |
April 23, 2018 |
|
|
6 |
NCT02959164 |
Recruiting |
Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma |
- Pancreatic Ductal Adenocarcinoma
- Sarcoma
|
- Drug: Decitabine
- Drug: Gemcitabine
|
Interventional |
Phase 1 |
- Laith Abushahin
- Holden Comprehensive Cancer Center
- University of Iowa
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity - To examine the toxicity related to the therapy by measuring the number of treatment related adverse events in patients
- Tumor Response Rate - Change at evaluations
- Disease control rate (DCR)
- (and 2 more...)
|
42 |
All |
18 Years and older (Adult, Senior) |
NCT02959164 |
201610750 |
|
December 2016 |
October 2018 |
October 2019 |
November 8, 2016 |
June 27, 2017 |
|
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
|
7 |
NCT02320292 |
Recruiting |
Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma |
- Stage I Grade 1 Follicular Lymphoma
- Stage I Grade 2 Follicular Lymphoma
- Stage II Grade 1 Contiguous Follicular Lymphoma
- (and 7 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Quality-of-Life Assessment
- Biological: Rituximab
- Radiation: Yttrium Y-90 Ibritumomab Tiuxetan
|
Interventional |
Phase 3 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete response (CR) rate at the 6-month disease assessment
- Incidence of adverse events assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Progression-free survival (PFS)
- (and 2 more...)
|
128 |
All |
18 Years and older (Adult, Senior) |
NCT02320292 |
LS138D NCI-2014-02476 P30CA015083 |
|
February 2015 |
January 2026 |
January 2026 |
December 19, 2014 |
February 6, 2018 |
|
- University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States - Mayo Clinic
Rochester, Minnesota, United States
|
8 |
NCT02905591 |
Not yet recruiting |
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC |
- Carcinoma, Non-Small-Cell Lung
- Non-Small Cell Lung Cancer
- Nonsmall Cell Lung Cancer
- (and 2 more...)
|
- Drug: Radiation Therapy
- Drug: Paclitaxel
- Drug: Carboplatin
- Drug: Ascorbic Acid
|
Interventional |
Phase 2 |
- Bryan Allen
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- (and 2 more...)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Progression free survival (PFS)
- Tumor response
- Adverse event frequency and categorization
|
46 |
All |
18 Years and older (Adult, Senior) |
NCT02905591 |
201712770 3P30CA086862 5U01CA140206 |
XACT-LUNG |
April 30, 2018 |
July 2024 |
July 2026 |
September 19, 2016 |
April 17, 2018 |
|
|
9 |
NCT03418038 |
Recruiting |
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma |
- High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Hodgkin Lymphoma
- (and 3 more...)
|
- Dietary Supplement: Ascorbic Acid
- Drug: Carboplatin
- Drug: Cisplatin
- (and 10 more...)
|
Interventional |
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- ORR (Arm C) defined as an objective status of CR or PR evaluated by RECIL criteria after 2 cycles of treatment
- Overall response rate (ORR) (Arms A and B) defined as an objective status of complete response (CR) or partial response (PR) evaluated by Response Evaluation Criteria in Lymphoma (RECIL) criteria after 2 courses of treatment in all arms
- Clinical benefit rate
- (and 6 more...)
|
151 |
All |
18 Years and older (Adult, Senior) |
NCT03418038 |
LS1781 NCI-2018-00057 P30CA015083 |
|
March 23, 2018 |
March 15, 2024 |
March 15, 2024 |
February 1, 2018 |
March 27, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Mayo Clinic in Florida
Jacksonville, Florida, United States - University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States - Mayo Clinic
Rochester, Minnesota, United States
|
10 |
NCT02905578 |
Not yet recruiting |
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) |
- Pancreatic Neoplasms
- Cancer of Pancreas
- Cancer of the Pancreas
- (and 4 more...)
|
- Drug: Gemcitabine
- Drug: nab-paclitaxel
- Drug: Pharmacological ascorbate
|
Interventional |
Phase 2 |
- Joseph J. Cullen
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- (and 3 more...)
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Progression free survival
- Tumor Response
- Adverse event frequency and categorization
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT02905578 |
201801759 3P30CA086862 5U01CA140206 |
|
May 28, 2018 |
December 31, 2023 |
December 31, 2025 |
September 19, 2016 |
March 19, 2018 |
|
|
11 |
NCT02876640 |
Recruiting |
Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer |
- Early-Stage Breast Carcinoma
- Grade 2 Invasive Breast Carcinoma
- Grade 3 Invasive Breast Carcinoma
|
- Other: Laboratory Biomarker Analysis
- Drug: Retinoid 9cUAB30
- Procedure: Therapeutic Conventional Surgery
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Absolute change in Ki-67 expression in breast epithelial cells of patients treated with 9cUAB30 assessed by immunohistochemistry
- Change in apoptosis in breast epithelial cells of patients treated with 9cUAB30 assessed by TUNEL assay and immunohistochemistry
- Change in gene expression of breast cancer samples using a custom gene panel from Nanostring Technologies
- Change in maximum concentration (Cmax)
|
40 |
Female |
18 Years and older (Adult, Senior) |
NCT02876640 |
NCI-2016-01293 N01-CN-2012-00033 UW16063 UWI2015-05-01 N01CN00033 P30CA014520 |
|
March 16, 2018 |
April 15, 2020 |
April 15, 2020 |
August 24, 2016 |
April 17, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States - University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, United States - (and 2 more...)
|
12 |
NCT01787409 |
Recruiting |
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency |
- Aggressive Non-Hodgkin Lymphoma
- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-Cell Lymphoma
- (and 12 more...)
|
- Dietary Supplement: Cholecalciferol
- Other: Laboratory Biomarker Analysis
|
Interventional |
Not Applicable |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event free survival (EFS) (Study I)
- Treatment free status (Study II)
- Bio-R response rate (Study II)
- (and 5 more...)
|
713 |
All |
18 Years and older (Adult, Senior) |
NCT01787409 |
LS1293 NCI-2013-00037 P30CA015083 |
|
March 2013 |
September 2018 |
September 2018 |
February 8, 2013 |
July 7, 2017 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Emory University/Winship Cancer Institute
Atlanta, Georgia, United States - University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States - (and 2 more...)
|
13 |
NCT01479283 |
Recruiting |
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) |
|
- Drug: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen
- Drug: 5-Days Prophylactic Cefazolin* Antibiotic Regimen
|
Interventional |
Phase 3 |
- McMaster University
- Orthopedic Research and Education Foundation
- The Physicians' Services Incorporated Foundation
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Surgical Site Infections
- Functional Outcome and Quality of Life
- Antibiotic-Related Complications
- (and 3 more...)
|
600 |
All |
12 Years and older (Child, Adult, Senior) |
NCT01479283 |
GHRT01 |
PARITY |
January 2013 |
December 2020 |
December 2020 |
November 24, 2011 |
May 25, 2017 |
|
- Stanford University Hospital and Clinics
Redwood City, California, United States - University of California San Francisco Medical Center
San Francisco, California, United States - University of Connecticut Health Center
Farmington, Connecticut, United States - (and 39 more...)
|
14 |
NCT02723006 |
Recruiting |
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma |
|
- Drug: TAK-580
- Drug: TAK-202
- Drug: vedolizumab
- (and 2 more...)
|
Interventional |
Phase 1 |
- Millennium Pharmaceuticals, Inc.
- Takeda
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Number of Dose-limiting Toxicities During the Dose-escalation Safety Lead-in Phase and Confirmatory Safety Phase
- Objective Response Rate (ORR) of the Dose-escalation Safety Lead-in Phase and Confirmatory Safety Phase
- Duration of Response (DOR)
- (and 3 more...)
|
156 |
All |
18 Years and older (Adult, Senior) |
NCT02723006 |
C28003 U1111-1177-4142 2015-005554-35 |
|
July 5, 2016 |
November 15, 2018 |
November 15, 2018 |
March 30, 2016 |
June 7, 2017 |
|
- University of Arizona Cancer Center
Tucson, Arizona, United States - University of California Los Angeles - Jonsson Comprehensive Cancer Center
Los Angeles, California, United States - University of California San Francisco - Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States - (and 13 more...)
|
15 |
NCT02348216 |
Recruiting |
A Phase 1-2 Multi-Center Study Evaluating Axicabtagene Ciloleucel in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) |
- Refractory Diffuse Large B Cell Lymphoma
- Refractory Primary Mediastinal B Cell Lymphoma
- Refractory Transformed Follicular Lymphoma
- (and 4 more...)
|
- Biological: axicabtagene ciloleucel
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1: Safety (Incidence of adverse events defined as dose-limiting toxicities (DLT)
- Phase 2: Overall Response Rate
- Phase 2 Expanded Cohorts: Safety
- (and 5 more...)
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT02348216 |
KTE-C19-101 |
ZUMA-1 |
January 2015 |
August 2018 |
March 2032 |
January 28, 2015 |
April 5, 2018 |
|
- Banner MD Anderson
Gilbert, Arizona, United States - City of Hope
Duarte, California, United States - UC San Diego Moores Cancer Center
La Jolla, California, United States - (and 27 more...)
|
16 |
NCT02194738 |
Recruiting |
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) |
- Large Cell Lung Carcinoma
- Lung Adenocarcinoma
- Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- (and 9 more...)
|
- Other: Cytology Specimen Collection Procedure
- Other: Laboratory Biomarker Analysis
|
Observational |
|
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
|
- Central clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105, as measured by rate of accrual
- Feasibility of research grade formalin-fixed, paraffin-embedded tissue collection for Center for Cancer Genomics (CCG) analysis, as measured by adequate specimens collected per month
- Disease free survival (DFS) rate for lung cancers which are wild-type for EGFR and ALK
- Agreement of local genotyping methods (direct sequencing of EGFR, ALK fluorescence in situ hybridization [FISH]) with central Clinical Laboratory Improvement Amendments genotyping
|
8300 |
All |
18 Years and older (Adult, Senior) |
NCT02194738 |
NCI-2014-01509 A151216 U10CA180821 U10CA180830 U10CA031946 |
|
August 18, 2014 |
September 28, 2021 |
September 28, 2021 |
July 18, 2014 |
April 20, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1330 more...)
|
17 |
NCT02993146 |
Recruiting |
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases |
- Metastatic Malignant Neoplasm
- Metastatic Malignant Neoplasm in the Brain
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Other: Quality-of-Life Assessment
- (and 2 more...)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of ropidoxuridine defined as the dose immediately below the lowest dose that produces dose limiting toxicities in at least 2 patients assessed by National Cancer Institute's Common Toxicity Criteria version 4
- Tumor response assessed by Response Evaluation Criteria in Solid Tumors 1.1
- Pharmacokinetic parameters of daily oral dosing of ropidoxuridine
- (and 4 more...)
|
47 |
All |
18 Years and older (Adult, Senior) |
NCT02993146 |
NCI-2016-01909 HP-00067789 9979 UM1CA186686 |
|
December 7, 2016 |
August 1, 2019 |
|
December 15, 2016 |
April 3, 2018 |
|
- UC San Diego Moores Cancer Center
La Jolla, California, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States - (and 4 more...)
|
18 |
NCT02749903 |
Recruiting |
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers |
|
|
Interventional |
Phase 2 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Astellas Pharma US, Inc.
- Alliance for Clinical Trials in Oncology
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- best overall response rate
- progression-free survival
- adverse events (The maximum grade for each type of adverse event will be summarized using CTCAE version 4.0.)
- adverse events (The frequency and percentage of grade 3+ adverse events will be summarized using CTCAE version 4.0.)
|
45 |
All |
18 Years and older (Adult, Senior) |
NCT02749903 |
A091404 NCI-2015-01706 |
|
June 2016 |
April 2018 |
|
April 25, 2016 |
April 9, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 280 more...)
|
19 |
NCT02143401 |
Recruiting |
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors |
- Cirrhosis
- Hepatitis B Infection
- Hepatitis C Infection
- (and 6 more...)
|
- Other: Laboratory Biomarker Analysis
- Biological: Navitoclax
- Other: Pharmacological Study
- Drug: Sorafenib Tosylate
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of navitoclax
- Incidence of adverse events as graded per NCI CTCAE v. 4.0
- Tumor response using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1
- (and 5 more...)
|
44 |
All |
18 Years and older (Adult, Senior) |
NCT02143401 |
NCI-2014-01043 MC1315 9608 UM1CA186686 |
|
November 7, 2014 |
November 1, 2018 |
|
May 21, 2014 |
March 15, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - University of Colorado Hospital
Aurora, Colorado, United States - (and 7 more...)
|
20 |
NCT02954796 |
Recruiting |
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Type, incidence, severity, seriousness, and relatedness of adverse events (including laboratory abnormalities)
- Incidence of dose-limiting toxicity
- Overall survival
- (and 7 more...)
|
75 |
All |
18 Years and older (Adult, Senior) |
NCT02954796 |
SGN352-001 |
|
December 2016 |
December 2018 |
December 2019 |
November 3, 2016 |
April 3, 2018 |
|
- Mayo Clinic Arizona
Scottsdale, Arizona, United States - City of Hope National Medical Center
Duarte, California, United States - Winship Cancer Institute / Emory University School of Medicine
Atlanta, Georgia, United States - (and 8 more...)
|
21 |
NCT01674140 |
Recruiting |
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer |
|
- Drug: anastrozole
- Drug: everolimus
- Drug: exemestane
- (and 5 more...)
|
Interventional |
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- IDFS using a stratified log-rank test, assessed up to 10 years
- OS estimates will be based on Kaplan-Meier procedures, assessed up to 10 years
- DRFS, assessed up to 10 years
- Toxicity based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, assessed up to 10 years
|
1900 |
All |
18 Years and older (Adult, Senior) |
NCT01674140 |
S1207 U10CA032102 NCI-2012-01995 |
e3 |
April 2013 |
December 2022 |
January 2030 |
August 28, 2012 |
March 21, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1432 more...)
|
22 |
NCT02713386 |
Recruiting |
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Serous Neoplasm
- (and 19 more...)
|
- Drug: Carboplatin
- Other: Laboratory Biomarker Analysis
- Drug: Paclitaxel
- (and 2 more...)
|
Interventional |
Phase 1 Phase 2 |
- NRG Oncology
- National Cancer Institute (NCI)
- NRG Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of hematologic (heme) dose-limiting toxicity assessed according to Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Phase I)
- Progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Phase II)
- Complete pathological response, defined as no evidence of disease on radiographic imaging at the time of radiographic tumor measurement (Phase II)
- (and 5 more...)
|
162 |
Female |
18 Years and older (Adult, Senior) |
NCT02713386 |
NRG-GY007 NCI-2016-00203 U10CA180868 |
|
May 18, 2016 |
September 30, 2020 |
|
March 18, 2016 |
February 16, 2018 |
|
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States - University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States - Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States - (and 8 more...)
|
23 |
NCT02750826 |
Recruiting |
Breast Cancer WEight Loss Study (BWEL Study) |
|
- Other: Health Education Program
- Other: Weight Loss Intervention
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Division of Cancer Control
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Invasive disease-free survival
- Overall survival
- Distant disease-free survival
- (and 20 more...)
|
3136 |
Female |
18 Years and older (Adult, Senior) |
NCT02750826 |
A011401 NCI-2015-01918 |
|
August 2016 |
May 2030 |
|
April 26, 2016 |
April 9, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 1259 more...)
|
24 |
NCT02883049 |
Recruiting |
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations |
- B Acute Lymphoblastic Leukemia
- Central Nervous System Leukemia
- Ph-Like Acute Lymphoblastic Leukemia
- (and 3 more...)
|
- Drug: Clofarabine
- Drug: Cyclophosphamide
- Drug: Cytarabine
- (and 14 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Comparison of disease-free survival (DFS) of children with high-risk (HR) B-acute lymphoblastic leukemia (ALL)
- DFS of children, adolescents, and young adults with very high-risk (VHR) B-ALL between arms
- Toxicity and tolerability of post-induction age-adjusted ITT compared to age-adjusted IT MTX in children with HR B-ALL
- (and 7 more...)
|
5956 |
All |
1 Year to 30 Years (Child, Adult) |
NCT02883049 |
NCI-2011-03797 CDR0000706370 AALL1131 COG-AALL1131 S12-01254 U10CA180886 U10CA098543 |
|
February 27, 2012 |
June 30, 2021 |
|
August 30, 2016 |
April 23, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama
Mobile, Alabama, United States - (and 236 more...)
|
25 |
NCT03080883 |
Recruiting |
Apixaban in Preventing Secondary Cancer Related Blood Clots in Cancer Patients Who Have Completed Anticoagulation Therapy |
- Deep Vein Thrombosis
- Malignant Neoplasm
- Metastatic Malignant Neoplasm
- Pulmonary Embolism
|
|
Interventional |
Phase 3 |
- Academic and Community Cancer Research United
- National Cancer Institute (NCI)
- Academic and Community Cancer Research United
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Proportion of patients who experience at least one bleeding event
- Proportion of patients who experienced at least one bleeding event
- Venous thromboembolism recurrence
|
370 |
All |
18 Years and older (Adult, Senior) |
NCT03080883 |
ACCRU-SC-1601 NCI-2017-00325 P30CA015083 |
|
July 14, 2017 |
May 1, 2020 |
May 1, 2020 |
March 15, 2017 |
March 16, 2018 |
|
- NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, United States - Carle Cancer Center
Urbana, Illinois, United States - University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States - (and 9 more...)
|
26 |
NCT01142427 |
Recruiting |
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
- Adult B Acute Lymphoblastic Leukemia
- Adult T Acute Lymphoblastic Leukemia
- Childhood B Acute Lymphoblastic Leukemia
- (and 3 more...)
|
- Other: Cytology Specimen Collection Procedure
- Other: Laboratory Biomarker Analysis
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Classification data for correlative studies
- Development of a central reference guide for required and research ALL studies
- Development of a risk classification system to be used to assign patients to treatment on COG frontline ALL treatment studies
- Development of mechanism for optional leukemia and germline specimens for current and future research
|
14250 |
All |
up to 30 Years (Child, Adult) |
NCT01142427 |
AALL08B1 NCI-2011-02235 PAALL08B1_A09PAMDREVW01 CDR0000674844 COG-AALL08B1 U10CA180886 U10CA098543 |
|
August 2010 |
January 2100 |
|
June 11, 2010 |
February 23, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama
Mobile, Alabama, United States - (and 238 more...)
|
27 |
NCT02166463 |
Recruiting |
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB or Stage IIIB-IVB Hodgkin Lymphoma |
- Ann Arbor Stage IIB Hodgkin Lymphoma
- Ann Arbor Stage IIIB Hodgkin Lymphoma
- Ann Arbor Stage IV Hodgkin Lymphoma
- (and 4 more...)
|
- Biological: Bleomycin Sulfate
- Drug: Brentuximab Vedotin
- Drug: Cyclophosphamide
- (and 8 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Event free survival (EFS), where events include disease progression or relapse, second malignancy, or death
- Proportion of patients with early response defined as no slow responding lesions (SRL) and no progressive disease (PD) at all sites determined by positron emission tomography (PET) per Deauville criteria through central review
- Proportion of patients needing protocol-directed radiation therapy (RT) defined as patients with slow responding lesions (SRL) or progressive disease (PD)
- Proportion of patients experiencing grade 3+ peripheral neuropathy assessed by modified Balis scale
|
600 |
All |
2 Years to 22 Years (Child, Adult) |
NCT02166463 |
NCI-2014-01223 s15-00950 AHOD1331 U10CA180886 |
|
March 16, 2015 |
November 30, 2019 |
November 30, 2019 |
June 18, 2014 |
April 23, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - (and 188 more...)
|
28 |
NCT02595944 |
Recruiting |
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) |
- Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- Stage II Non-Small Cell Lung Cancer AJCC v7
- Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
- (and 2 more...)
|
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Disease-free survival
- Incidence of toxicity graded according to Common Terminology Criteria for Adverse Events version 4.0
|
714 |
All |
18 Years and older (Adult, Senior) |
NCT02595944 |
NCI-2015-01916 EA5142 s16-02074 U10CA180820 |
ANVIL |
May 6, 2016 |
July 1, 2024 |
|
November 4, 2015 |
April 18, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 729 more...)
|
29 |
NCT02446600 |
Recruiting |
Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- BRCA Rearrangement
- Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
- (and 12 more...)
|
- Drug: Carboplatin
- Drug: Cediranib Maleate
- Drug: Gemcitabine Hydrochloride
- (and 6 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- AstraZeneca
- National Cancer Institute (NCI)
|
NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival determined using Response Evaluation Criteria in Solid Tumors version 1.1 criteria
- Overall survival
- Frequency and severity of adverse effects
- Patient reported scores of disease-related symptoms as measured by the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 Disease-Related Symptom-Physical
|
549 |
Female |
19 Years and older (Adult, Senior) |
NCT02446600 |
NCI-2015-00606 NRG-GY004 s16-01480 U10CA180868 |
|
February 4, 2016 |
December 31, 2019 |
|
May 18, 2015 |
April 23, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Alaska Women's Cancer Care
Anchorage, Alaska, United States - (and 357 more...)
|
30 |
NCT02628405 |
Recruiting |
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma |
- CD20 Positive
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- (and 5 more...)
|
- Drug: Carboplatin
- Drug: Etoposide
- Drug: Ifosfamide
- (and 3 more...)
|
Interventional |
Phase 1 Phase 2 |
- Academic and Community Cancer Research United
- National Cancer Institute (NCI)
- Academic and Community Cancer Research United
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients of the addition of lenalidomide to rituximab-ifosfamide-carboplatin-etoposide (Phase I)
- Overall response rate defined as a complete metabolic response or partial metabolic response (Phase II)
- Toxicity profile defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment as measured by Common Terminology Criteria for Adverse Events version 4.0 (Phase I)
- (and 4 more...)
|
63 |
All |
18 Years and older (Adult, Senior) |
NCT02628405 |
RU051417I NCI-2015-01990 P30CA015083 |
|
May 20, 2016 |
May 20, 2018 |
January 20, 2023 |
December 11, 2015 |
March 29, 2018 |
|
- Mayo Clinic in Florida
Jacksonville, Florida, United States - Illinois CancerCare-Peoria
Peoria, Illinois, United States - Carle Cancer Center NCI Community Oncology Research Program
Urbana, Illinois, United States - (and 11 more...)
|
31 |
NCT02567435 |
Recruiting |
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma |
- Alveolar Rhabdomyosarcoma
- Botryoid-Type Embryonal Rhabdomyosarcoma
- Embryonal Rhabdomyosarcoma
- (and 4 more...)
|
- Drug: Cyclophosphamide
- Biological: Dactinomycin
- Drug: Irinotecan Hydrochloride
- (and 5 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free survival (EFS)
- Overall survival (OS)
|
337 |
All |
up to 40 Years (Child, Adult) |
NCT02567435 |
NCI-2015-01644 ARST1431 U10CA180886 |
|
May 23, 2016 |
November 1, 2022 |
|
October 5, 2015 |
April 23, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 298 more...)
|
32 |
NCT02839707 |
Recruiting |
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- High Grade Fallopian Tube Serous Adenocarcinoma
- (and 10 more...)
|
- Drug: Atezolizumab
- Biological: Bevacizumab
- Other: Laboratory Biomarker Analysis
- (and 2 more...)
|
Interventional |
Phase 2 Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of dose limiting toxicities (DLT) of experimental regimens graded using Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.0 (CTCAE version 5.0 will be used beginning April 1, 2018)
- Progression free survival (PFS) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 criteria (Phase II)
- Overall survival (OS) (Phase III)
- (and 10 more...)
|
488 |
Female |
18 Years and older (Adult, Senior) |
NCT02839707 |
NCI-2016-01081 NRG-GY009 U10CA180868 UG1CA189867 |
|
May 12, 2017 |
June 30, 2023 |
June 30, 2023 |
July 21, 2016 |
April 20, 2018 |
|
- University of Colorado Hospital
Aurora, Colorado, United States - Augusta University Medical Center
Augusta, Georgia, United States - John H Stroger Jr Hospital of Cook County
Chicago, Illinois, United States - (and 17 more...)
|
33 |
NCT02201992 |
Recruiting |
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) |
- ALK Gene Rearrangement
- ALK Gene Translocation
- ALK Positive
- (and 5 more...)
|
- Other: Clinical Observation
- Drug: Crizotinib
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 3 |
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Disease free survival (DFS)
- Toxicity rates, determined using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
378 |
All |
18 Years and older (Adult, Senior) |
NCT02201992 |
E4512 NCI-2014-01507 s16-02072 U10CA180820 U10CA180830 U10CA021115 U24CA196172 |
|
August 18, 2014 |
May 1, 2022 |
|
July 28, 2014 |
December 11, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1286 more...)
|
34 |
NCT02193282 |
Recruiting |
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) |
- ALK Gene Rearrangement
- EGFR Exon 19 Deletion Mutation
- EGFR NP_005219.2:p.L858R
- (and 5 more...)
|
- Other: Clinical Observation
- Drug: Erlotinib Hydrochloride
- Other: Laboratory Biomarker Analysis
- Other: Placebo
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Disease free survival (DFS) rate, defined as the proportion of patients alive and disease free at 2 years from the date of randomization
- Overall survival (OS) rate defined as the proportion of patients alive at 5 years from date of randomization
- (and 3 more...)
|
450 |
All |
18 Years and older (Adult, Senior) |
NCT02193282 |
NCI-2014-01508 s16-02079 CALGB A081105 A081105 U10CA180821 U10CA180830 U10CA031946 |
|
August 18, 2014 |
November 4, 2020 |
|
July 17, 2014 |
April 23, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1302 more...)
|
35 |
NCT03377556 |
Recruiting |
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer |
- ATM Gene Mutation
- ATR Gene Mutation
- BARD1 Gene Mutation
- (and 18 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Drug: Talazoparib
|
Interventional |
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate assessed by Response Evaluation Criteria in Solid Tumors 1.1 (Design #2)
- Duration of response (Design #2)
- Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Design #2)
- (and 2 more...)
|
64 |
All |
Child, Adult, Senior |
NCT03377556 |
S1400G NCI-2017-00135 U10CA180888 |
|
February 7, 2017 |
May 1, 2022 |
December 2024 |
December 19, 2017 |
April 20, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1113 more...)
|
36 |
NCT01872975 |
Recruiting |
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery |
- Stage IB Breast Cancer
- Stage II Breast Cancer
|
- Radiation: regional nodal XRT
- Radiation: chestwall XRT
- Radiation: WBI
|
Interventional |
Not Applicable |
- NSABP Foundation Inc
- National Cancer Institute (NCI)
- Radiation Therapy Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- IBC-RFI
- OS
- LRRFI
- (and 6 more...)
|
1636 |
Female |
18 Years and older (Adult, Senior) |
NCT01872975 |
NSABP-B-51 NCI-2012-03198 U10CA012027 |
|
August 2013 |
July 2023 |
August 2028 |
June 7, 2013 |
May 16, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 518 more...)
|
37 |
NCT01901094 |
Recruiting |
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy |
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
|
- Procedure: Axillary Lymph Node Dissection (ALND)
- Radiation: Nodal Radiation Therapy
- Radiation: Axillary Radiation Therapy
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Invasive breast cancer recurrence-free interval (IBC-RFI)
- Overall survival
- Ipsilateral/local/regional invasive breast cancer recurrence (ILR-REC)
|
2918 |
All |
18 Years and older (Adult, Senior) |
NCT01901094 |
A011202 U10CA031946 NCI-2013-00875 |
|
February 2014 |
January 2024 |
|
July 17, 2013 |
April 9, 2018 |
|
- Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - Southern Cancer Center PC-Providence
Mobile, Alabama, United States - (and 1091 more...)
|
38 |
NCT03269669 |
Recruiting |
Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma |
- Grade 1 Follicular Lymphoma
- Grade 2 Follicular Lymphoma
- Grade 3a Follicular Lymphoma
- (and 2 more...)
|
- Drug: Cyclophosphamide
- Drug: Doxorubicin Hydrochloride
- Other: Laboratory Biomarker Analysis
- (and 5 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete response (CR)
- Progression-free survival
- Overall survival
- (and 4 more...)
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT03269669 |
NCI-2017-00009 S1608 U10CA180888 |
|
August 10, 2017 |
December 31, 2022 |
December 31, 2022 |
September 1, 2017 |
April 20, 2018 |
|
- Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - Alaska Women's Cancer Care
Anchorage, Alaska, United States - (and 269 more...)
|
39 |
NCT02523014 |
Recruiting |
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas |
- Intracranial Meningioma
- Recurrent Meningioma
- NF2 Gene Mutation
|
- Drug: vismodegib
- Drug: GSK2256098
|
Interventional |
Phase 2 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- GlaxoSmithKline
- (and 3 more...)
|
Other / NIH / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Response rate defined as a confirmed complete response (CR) or partial response (PR)
- Overall survival (OS)
- Incidence of adverse events according to National Cancer Institute CTCAE version 4.0
|
69 |
All |
18 Years and older (Adult, Senior) |
NCT02523014 |
A071401 NCI-2015-00546 |
|
August 2015 |
August 2019 |
|
August 14, 2015 |
April 9, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 619 more...)
|
40 |
NCT03141684 |
Recruiting |
Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery |
- Metastatic Alveolar Soft Part Sarcoma
|
- Drug: Atezolizumab
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate evaluated using Response Evaluation Criteria in Solid Tumors version 1.1
- Duration of response using Response Evaluation Criteria in Solid Tumors version 1.1
- Progression free survival evaluated using Response Evaluation Criteria in Solid Tumors version 1.1
- (and 2 more...)
|
35 |
All |
6 Years and older (Child, Adult, Senior) |
NCT03141684 |
NCI-2016-01040 17-C-007 CC 17-C-0074 10005 ZIABC011078 |
|
March 3, 2017 |
December 1, 2018 |
December 1, 2018 |
May 5, 2017 |
April 10, 2018 |
|
- Mayo Clinic Hospital
Phoenix, Arizona, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Los Angeles County-USC Medical Center
Los Angeles, California, United States - (and 33 more...)
|
41 |
NCT02921256 |
Recruiting |
Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer |
- Rectal Adenocarcinoma
- Stage II Rectal Cancer AJCC v7
- Stage III Rectal Cancer AJCC v7
|
- Drug: Capecitabine
- Drug: Fluorouracil
- Radiation: Intensity-Modulated Radiation Therapy
- (and 4 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in NAR score
- OS
- DFS
- (and 11 more...)
|
174 |
All |
18 Years and older (Adult, Senior) |
NCT02921256 |
NCI-2016-00222 NRG-GI002 s17-00197 U10CA180868 |
|
October 12, 2016 |
April 30, 2019 |
|
October 3, 2016 |
April 23, 2018 |
|
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - (and 515 more...)
|
42 |
NCT02785952 |
Recruiting |
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers |
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
|
- Biological: Ipilimumab
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
- (and 2 more...)
|
Interventional |
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Investigator-assessed progression-free survival as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (Design #1, Phase II)
- Less than 33% improvement in median investigator-assessed progression-free survival as defined as Response Evaluation Criteria in Solid Tumors version 1.1 (Design #1, Phase III)
- Overall survival
- (and 4 more...)
|
350 |
All |
18 Years and older (Adult, Senior) |
NCT02785952 |
S1400I NCI-2016-00050 U10CA180888 |
|
December 18, 2015 |
April 1, 2022 |
April 1, 2022 |
May 30, 2016 |
April 10, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1177 more...)
|
43 |
NCT02828358 |
Recruiting |
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement |
- Acute Leukemia of Ambiguous Lineage
- Childhood B Acute Lymphoblastic Leukemia
- KMT2A Gene Rearrangement
- Mixed Phenotype Acute Leukemia
|
- Drug: Azacitidine
- Drug: Cyclophosphamide
- Drug: Cytarabine
- (and 12 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of adverse events of azacitidine and combination chemotherapy, graded according to Common Terminology Criteria for Adverse Events 4.0 (version 5.0 beginning April 1, 2018)
- Biologic activity, defined as global deoxyribonucleic acid (DNA) methylation change in peripheral blood mononuclear cells (PBMC)s
|
116 |
All |
up to 364 Days (Child) |
NCT02828358 |
NCI-2016-00973 s17-00488 AALL15P1 U10CA180886 |
|
March 27, 2017 |
September 30, 2019 |
September 30, 2019 |
July 11, 2016 |
April 10, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of South Alabama
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 159 more...)
|
44 |
NCT02601209 |
Recruiting |
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma |
- High Grade Sarcoma
- Metastatic Leiomyosarcoma
- Metastatic Malignant Peripheral Nerve Sheath Tumor
- (and 8 more...)
|
- Drug: Pazopanib Hydrochloride
- Drug: Sapanisertib
|
Interventional |
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of sapanisertib (Phase I)
- Progression-free survival (PFS) (Phase II)
- Incidence of adverse events graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- (and 5 more...)
|
137 |
All |
18 Years and older (Adult, Senior) |
NCT02601209 |
NCI-2015-01929 A091304 U10CA180821 |
|
November 30, 2015 |
September 1, 2020 |
|
November 10, 2015 |
April 10, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 419 more...)
|
45 |
NCT02500797 |
Recruiting |
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery |
- Dedifferentiated Liposarcoma
- Gastrointestinal Stromal Tumor
- Metastatic Liposarcoma
- (and 9 more...)
|
- Biological: Ipilimumab
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
- Other: Quality-of-Life Assessment
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Confirmed response rate estimated as the number of patients having a best objective tumor status of complete response (CR) or partial response (PR) lasting at least 4 weeks, divided by the number of evaluable patients
- Adverse event (AE) rates graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (version 5.0 beginning April 1, 2018)
- Duration of response
- (and 3 more...)
|
195 |
All |
18 Years and older (Adult, Senior) |
NCT02500797 |
NCI-2015-00260 A091401 U10CA180821 |
|
July 30, 2015 |
January 30, 2022 |
|
July 17, 2015 |
April 17, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 627 more...)
|
46 |
NCT02306161 |
Recruiting |
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma |
- Metastatic Ewing Sarcoma
- Metastatic Malignant Neoplasm in the Bone
- Metastatic Malignant Neoplasm in the Bone Marrow
- (and 3 more...)
|
- Drug: Cyclophosphamide
- Drug: Doxorubicin Hydrochloride
- Drug: Etoposide
- (and 8 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to adverse analytic event (event-free survival [EFS]), defined to be disease-related event, diagnosis of a second malignant neoplasm, or death
- Overall Survival
- Overall toxicity of the addition of ganitumab to vincristine sulfate, doxorubicin hydrochloride and cyclophosphamide (VDC)/ifosfamide and etoposide (IE), using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- (and 6 more...)
|
330 |
All |
up to 50 Years (Child, Adult) |
NCT02306161 |
NCI-2014-02380 AEWS1221 s15-00442 U10CA180886 U10CA098543 |
|
December 8, 2014 |
December 31, 2018 |
|
December 3, 2014 |
April 23, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of South Alabama
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 314 more...)
|
47 |
NCT02177695 |
Recruiting |
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer |
|
- Drug: Gemcitabine
- Drug: Cisplatin
- Drug: Methotrexate
- (and 3 more...)
|
Interventional |
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The relationship of dose-dense methotrexate, vinblastin, doxorubicin, and cisplatin (DDMVAC)- and gemcitabine+cisplatin (GC)- specific CO-eXpression ExtrapolatioN (COXEN) scores.
- Predictability of the CO-eXpression ExtrapolatioN (COXEN) score to direct which of the two regimens the patient should receive: gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastin, doxorubicin, and cisplatin (DDMVAC)
- Overall survival
- (and 2 more...)
|
184 |
All |
18 Years and older (Adult, Senior) |
NCT02177695 |
S1314 NCI-2014-00850 U10CA180888 |
COXEN |
July 2014 |
February 2020 |
October 2022 |
June 30, 2014 |
July 13, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - University of Arizona Cancer Center at Saint Joseph's
Phoenix, Arizona, United States - (and 564 more...)
|
48 |
NCT02154490 |
Recruiting |
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer |
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
|
- Drug: Docetaxel
- Biological: Durvalumab
- Drug: Erlotinib Hydrochloride
- (and 10 more...)
|
Interventional |
Phase 2 Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Investigator-assessed progression-free survival as defined by Response Evaluation Criteria in Solid Tumors 1.1 (Design #1, Phase II)
- Investigator-assessed progression-free survival in patients with advanced stage refractory squamous cell carcinoma of the lung randomized to receive investigational therapy vs standard therapy (Design #2,Phase III,Option for Biomarker-driven sub-studies)
- Less than 33% improvement in median investigator-assessed progression-free survival as defined as Response Evaluation Criteria in Solid Tumors 1.1 (Design #1, Phase III)
- (and 13 more...)
|
10000 |
All |
18 Years and older (Adult, Senior) |
NCT02154490 |
S1400 NCI-2014-00627 S1400A S1400E S1400I S1400C S1400D S1400B U10CA180888 |
|
June 16, 2014 |
April 1, 2022 |
April 1, 2022 |
June 3, 2014 |
March 21, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 972 more...)
|
49 |
NCT02115282 |
Recruiting |
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic |
- Estrogen Receptor Positive
- HER2/Neu Negative
- Male Breast Carcinoma
- (and 5 more...)
|
- Drug: Entinostat
- Drug: Exemestane
- Drug: Goserelin Acetate
- (and 4 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- PFS defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1)
- OS
- Objective response, defined as the proportion of patients with complete response (CR) or partial response (PR) among all patients assessed per RESIST v1.1
- (and 2 more...)
|
600 |
All |
18 Years and older (Adult, Senior) |
NCT02115282 |
NCI-2014-00746 ECOG-E2112 E2112 U10CA180820 U10CA021115 U24CA196172 |
|
March 29, 2014 |
January 14, 2021 |
|
April 16, 2014 |
April 18, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Fowler Family Center for Cancer Care
Jonesboro, Arkansas, United States - Mercy San Juan Medical Center
Carmichael, California, United States - (and 653 more...)
|
50 |
NCT02180867 |
Recruiting |
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery |
- Adult Fibrosarcoma
- Alveolar Soft Part Sarcoma
- Angiomatoid Fibrous Histiocytoma
- (and 33 more...)
|
- Drug: Doxorubicin Hydrochloride
- Drug: Ifosfamide
- Other: Laboratory Biomarker Analysis
- (and 4 more...)
|
Interventional |
Phase 2 Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Potential benefit for chemoradiotherapy plus pazopanib hydrochloride defined as protocol week 13 pathologic response (Phase II)
- Potential benefit for radiotherapy plus pazopanib hydrochloride defined as protocol week 10 pathologic response (Phase II/III)
- Event-free survival (EFS) (Phase III)
- (and 4 more...)
|
340 |
All |
2 Years and older (Child, Adult, Senior) |
NCT02180867 |
NCI-2014-01340 s14-02023 ARST1321 U10CA180830 U10CA180886 U10CA098543 |
|
July 11, 2014 |
June 13, 2018 |
|
July 3, 2014 |
April 23, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - The Kirklin Clinic at Acton Road
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 364 more...)
|